Dydrogesterone versus medroxyprogesterone acetate co-treatment ovarian stimulation for IVF: a matched cohort study of 236 freeze-all-IVF cycles

References

• Alper MM, Fauser BC. 2017. Ovarian stimulation protocols for IVF: is more better than less? Reproductive Biomedicine Online 34:345–353.
   PubMed Web of Science ®Google Scholar
• Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. 2011. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod 26:1270–1283.
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang Y, Sun L, Zhang S, Chai W, Hong Q, et al. 2017. Controlled ovulation of the dominant follicle using progestin in minimal stimulation in poor responders. Reproductive Biology and Endocrinology 15:71.
   PubMed Web of Science ®Google Scholar
• D'Arpe S, Di Feliciantonio M, Candelieri M, Franceschetti S, Piccioni MG, Bastianelli C. 2016. Ovarian function during hormonal contraception assessed by endocrine and sonographic markers: a systematic review. Reprod Biomed Online 33:436–448.
   PubMed Web of Science ®Google Scholar
• Dessolle L, Fréour T, Barrière P, Daraï E, Ravel C, Jean M, et al. 2010. A cycle-based model to predict blastocyst transfer cancellation. Human Reproduction 25:598–604.
   PubMed Web of Science ®Google Scholar
• Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. 2016. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod 31:370–376.
   PubMed Web of Science ®Google Scholar
• European and Middle East Orgalutran Study Group 2001. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16:644–651.
   PubMed Web of Science ®Google Scholar
• Fatemi HM, Blockeel C, Devroey P. 2012. Ovarian stimulation: today and tomorrow. Current Pharmaceutical Biotechnology 13:392–397.
   PubMed Web of Science ®Google Scholar
• Gardner DK, Schoolcraft WB. 1999. In vitro culture of human blastocysts. In: Jansen R, Mortimer D, editors. Toward reproductive certainty: fertility and genetics beyond. London: Parthenon Publishing. p. 378–388.
   Google Scholar
• Guo H, Wang Y, Chen Q, Chai W, Sun L, Ai A, et al. 2017. Use of medroxyprogesterone acetate in women with ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization. Scientific Reports 7:11927.
   PubMed Web of Science ®Google Scholar
• Hayden C. 2008. GnRH analogues: applications in assisted reproductive techniques. European Journal of Endocrinology 159:S17–S25.
   PubMed Web of Science ®Google Scholar
• Huang J, Xie Q, Lin J, Lu X, Zhu J, Gao H, et al. 2020. Progestin-primed ovarian stimulation with dydrogesterone versus medroxyprogesterone acetate in women with polycystic ovarian syndrome for in vitro fertilization: a retrospective cohort study. Drug Design, Development and Therapy 13:4461–4470.
   Web of Science ®Google Scholar
• Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O, et al. 2018. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet 298:663–671.
   PubMed Web of Science ®Google Scholar
• Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. 2015. Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility 104:62–70.
   PubMed Web of Science ®Google Scholar
• Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, et al. 2014. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertility and Sterility 101:105–111.
   PubMed Web of Science ®Google Scholar
• La Marca A, Capuzzo M. 2019. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Reproductive Biomedicine Online 39:321–331.
   PubMed Web of Science ®Google Scholar
• Massin N. 2017. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Human Reproduction Update 23:211–220.
   PubMed Web of Science ®Google Scholar
• O'Neill KE, Senapati S, Maina I, Gracia C, Dokras A. 2016. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. Journal of Assisted Reproduction and Genetics 33:1175–1184.
   PubMed Web of Science ®Google Scholar
• Orvieto R. 2015. Triggering final follicular maturation–hCG, GnRH-agonist or both, when and to whom? J Ovarian Res 21: 60.
   Web of Science ®Google Scholar
• Ozgur K, Berkkanoglu M, Bulut H, Donmez L, Coetzee K. 2020. Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all-IVF cycles. [Published online ahead of print, 22 July 2020]. Journal of Assisted Reproduction and Genetics 37:2337–2345.
   PubMed Web of Science ®Google Scholar
• Ozgur K, Berkkanoglu M, Bulut H, Humaidan P, Coetzee K. 2016. Agonist depot versus OCP programming of frozen embryo transfer: a retrospective analysis of freeze-all cycles. Journal of Assisted Reproduction and Genetics 33:207–214.
   PubMed Web of Science ®Google Scholar
• Ozgur K, Bulut H, Berkkanoglu M, Donmez L, Coetzee K. 2019. Prediction of live birth and cumulative live birth rates in freeze-all-IVF treatment of a general population. Journal of Assisted Reproduction and Genetics 36:685–696.
   PubMed Web of Science ®Google Scholar
• Ozgur K, Bulut H, Berkkanoglu M, Humaidan P, Coetzee K. 2018. Artificial cryopreserved embryo transfer cycle success depends on blastocyst developmental rate and progesterone timing. Reproductive Biomedicine Online 36:269–276.
   PubMed Web of Science ®Google Scholar
• Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Müller-Vieira U, Sonneveld E, et al. 2011. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids 76:607–615.
   PubMed Web of Science ®Google Scholar
• Roque M, Haahr T, Geber S, Esteves SC, Humaidan P. 2019. Fresh versus elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes. Human Reproduction Update 25:2–14.
   PubMed Web of Science ®Google Scholar
• Roque M. 2015. Freeze-all policy: is it time for that? Journal of Assisted Reproduction and Genetics 32:171–176.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. 2008. Classification and pharmacology of progestins. Maturitas 61:171–180.
   PubMed Web of Science ®Google Scholar
• Stone BA, March CM, Ringler GE, Baek KJ, Marrs RP. 2014. Casting for determinants of blastocyst yield and of rates of implantation and of pregnancy after blastocyst transfers. Fertility and Sterility 102:1055–1064.
   PubMed Web of Science ®Google Scholar
• Sun L, Ye J, Wang Y, Chen Q, Cai R, Fu Y, et al. 2018. Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Scientific Reports 8:13835.
   PubMed Web of Science ®Google Scholar
• Wang L, Yin M, Liu Y, Chen Q, Wang Y, Ai A, et al. 2017. Effect of Frozen Embryo Transfer and Progestin-primed Ovary Stimulation on IVF outcomes in women with high body mass index. Scientific Reports 7:7447.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y. 2016. Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine 95:e2939.
   PubMed Web of Science ®Google Scholar
• Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, et al. 2018. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Human Reproduction 33:229–237.
   PubMed Web of Science ®Google Scholar
• Zhu X, Fu Y. 2017. Use of dydrogesterone during controlled ovarian hyperstimulation in normal ovulatory women treated for in vitro fertilization or intracytoplasmic sperm injection treatments. Fertility and Sterility 108:e226–e227.
   Web of Science ®Google Scholar
• Zhu X, Zhang X, Fu Y. 2015. Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore) 94:e909.
   PubMed Web of Science ®Google Scholar